B-type natriuretic peptide and cirrhosis progression

Area of Science:

• Cardiology
• Hepatology
• Biomarkers

Background:

• Brain natriuretic peptide (BNP) is a known marker for cardiac dysfunction and heart failure mortality.
• Elevated BNP levels are observed in liver cirrhosis, but its prognostic significance in this condition is unclear.
• Cirrhosis staging and complications are critical factors influencing patient outcomes.

Purpose of the Study:

• To investigate the relationship between serum BNP levels and the stage of liver cirrhosis.
• To determine if BNP levels can predict 1-year all-cause mortality in patients with cirrhosis.
• To explore the correlation between BNP levels and specific cirrhosis-related complications.

Main Methods:

• A study involving 92 patients with varying stages of liver cirrhosis and 81 age- and gender-matched controls.
• Measurement of serum BNP levels and cardiac physical examinations at admission.
• 12-month follow-up of 89 patients post-discharge to assess all-cause mortality, utilizing univariate and multivariate Cox regression analyses.

Main Results:

• Median BNP levels were significantly higher in cirrhosis patients (167.0 pg/mL) compared to controls (34.8 pg/mL).
• Serum BNP levels positively correlated with Child score, esophageal varices grade, spontaneous bacterial peritonitis history, ascites, and collateral circulation.
• Elevated BNP levels (above median) were associated with increased 1-year mortality (log rank P = 0.025).

Conclusions:

• Serum BNP levels are significantly correlated with the stage and severity of liver cirrhosis.
• BNP levels emerge as a significant predictor of 1-year all-cause mortality in patients with liver cirrhosis.
• BNP measurement may aid in risk stratification and clinical outcome prediction for liver cirrhosis patients.